Conférences - Pharmacologie et développement des médicaments - États-Unis

Conference-Service.com met à la disposition de ses visiteurs des listes de conférences et réunions dans le domaine scientifique. Ces listes sont publiées pour le bénéfice des personnes qui cherchent une conférence, mais aussi, bien sûr, pour celui des organisateurs. Noter que, malgré tout le soin que nous apportons à la vérification des données entrées dans nos listes, nous ne pouvons accepter de responsabilité en ce qui concerne leur exactitude ou étendue. Pensez donc à vérifier les informations présentées avec les organisateurs de la conférence ou de la réunion avant de vous engager à y participer!

Les organisateurs peuvent soumettre une réunion ou une conférence pour inclusion dans nos listes, et ceci gratuitement.

1.
 
Vaccines-2017 — International Conference on Vaccines-2017
ID
811316
Dates
20 fév 2017 - 22 fév 2017
Lieu
Baltimore, États-Unis
Résumé
This scientific conference will bring an opportunity to share potential benefits and limitations of vaccines in preventing and control of infectious and non-infectious diseases thereby enhancing the quality and longevity of life.Vaccines 2017 mainly showcases comprehensive approaches in Vaccines and research, virology. vaccine conference includes Plenary lectures, Keynote lectures and short courses by eminent personalities from around the world in addition to contributed papers both oral and poster presentations
Contact
James Martin;     Tél.: [1-302-231-6959];     Email.: Vaccines@madrige.com
Sujets
Vaccines, virology, Infectious and non infectious diseases, Therapeutic Medicines
Sujets apparentés
2.
 
Spotlight on Post Market Surveillance - By AtoZ Compliance
ID
879183
Date de début
23 fév 2017
Lieu
Webinar, États-Unis
Résumé
This webinar will discuss the essentials of Post Market Surveillance, how you can develop your capabilities and how PMS can provide you with important information to improve your device, better service your customers, and reduce the risk of adverse events.

Post Market Surveillance (PMS) is the practice and system of monitoring the safety awareness training of a medical device after it has been released on the market.

It relies on several foundations including unique device identifiers (UDI), electronic health records and medical device reporting, device registries, and advance methods for evidence generation, data analysis and vigilance awareness training. It is a system that continues to develop and improve.

Contact
AtoZ Compliance;     Tél.: [8444141400];     Email.: referrals@atozcompliance.com
Sujets
pharmacovigilance training online, safety awareness training, vigilance awareness training, Post Market Surveillance and Vigilance Webinar
3.
 
Frontiers in Cancer Immunotherapy
ID
824370
Dates
27 fév 2017 - 28 fév 2017
Lieu
New York, NY, États-Unis
Résumé
This 2-day scientific symposium will explore emerging findings in basic science, translational research, and clinical studies to improve immunotherapeutic approaches in cancer treatment. The event will convene basic, preclinical, and clinical researchers active in the field of cancer immunotherapy, alongside industry representatives and government stakeholders. Dr. James Allison, Executive Director of the Immunotherapy Platform at the University of Texas MD Anderson Cancer Center and a pioneer in the field of cancer immunotherapy, will commence the conference with a Keynote Address. Plenary speakers will present on an array of topics, including: the evaluation of combination therapy strategies to improve clinical benefit; the development of immune-monitoring strategies for the identification of relevant prognostic and predictive biomarkers; the development of strategies to overcome immune tolerance; and the incorporation of genomics into immunotherapeutic research and clinical trials.
Sujets
Immunotherapy, Oncology, Immunology, Therapeutics, Clinical Trials, Vaccines, Diagnostics, Biomarkers, Genomics, Epigenomics, Epigenetics, Drug Discovery, Cancer
4.
 
Chemical Development & Scale-Up in the Fine Chemical & Pharmaceutical Industries
ID
858699
Dates
01 mar 2017 - 03 mar 2017
Lieu
Pasadena, California, États-Unis
5.
 
Seminar on the DHF, Technical File and Design Dossier - Similarities, Differences and the Future
ID
857601
Dates
02 mar 2017 - 03 mar 2017
Lieu
Las Vegas, NV, États-Unis
Contact
Event Manager;     Tél.: [(800) 447-9407];     Email.: support@globalcompliancepanel.com
Sujets
The Design History File, Device History Record, The Device Master Record, EU’s Medical Device Directive, Technical File Design Dossier, U.S. FDA’s DHF, FDA Compliance, FDA Regulations, Risk Analysis, Risk Management
6.
 
FDA's Regulation of Regenerative Medicine including Stem Cell Treatments, Tissue Engineering and Gene Therapies
ID
876730
Dates
02 mar 2017 - 03 mar 2017
Lieu
Boston, États-Unis
Résumé
Stem cells harness the power to differentiate into numerous cells upon stimulation. This has led to their wide exploration across all of medicine, including high risk diseases. Of course, significant scientific breakthroughs in the use of stem cells to prevent, diagnose, and treat numerous diseases has caused numerous start-up companies to form. Despite, such promise, the FDA has yet to approve stem cell therapies for a wide range of diseases, except cord blood-derived hematopoietic progenitor cells for certain indications. This tutorial will provide an historical context for the use of stem cells in medicine, where the field has been and where it is going. It will also provide the few examples of FDA approved use of stem cells in medicine and what is needed for the field to progress. For example, in 2006, the U.S. FDA implemented regulations governing the use of human cells, tissues, and cellular and tissue-based products in humans including bone, ligament, skin, dura mater, stem cells, cartilage cells, and various other cellular and tissue-based products. Currently, there is an ongoing debate in industry on how such therapies should be regulated, in particular by the FDA or under the practice of medicine, under federal law or state law, and as drugs or simply biologics.Note: Use coupon code < NB5SQH8N > and get 10% off on registration.
Contact
Referral;     Tél.: [8887172436];     Email.: referral@complianceonline.com
Sujets
Regenerative medicine regulations, Stem Cell Treatments, biomaterials, FDA regulates regenerative treatments and therapies, good manufacturing
7.
 
Understanding the FDA's Regulation of HCT/Ps and Successful Product Development Strategies
ID
876740
Dates
02 mar 2017 - 03 mar 2017
Lieu
Boston, États-Unis
Résumé
In 1997, the FDA proposed a comprehensive regulatory program for Human Cells, Tissues and Cellular- and Tissue-Based Products (HCT/Ps) outlining the registration and listing procedures for HCT/Ps. This program also differentiates between HCT/Ps that will be regulated via the traditional pathway and those that will undergo approval as new drugs, biologics or devices. In this seminar, we'll discuss the historical context for the use of HCT/Ps in medicine as well as how the HCT/P market is evolving. You will be shown examples of the FDA-approved use of HCT/Ps and what is required for successful product development. This course will also provide an overview of the health authority regulating HCT/Ps, discuss the regulations that govern HCT/Ps, discuss potential product development strategies and provide an overview of product development in the United States.Note: Use coupon code < NB5SQH8N > and get 10% off on registration.
Contact
Referral;     Tél.: [8887172436];     Email.: referral@complianceonline.com
Sujets
FDA regulatory oversight of HCT/Ps, tissue reference group, approval process, good tissue practice, good manufacturing practice, quality system regulations
8.
 
Keystone Symposia - Kinases: Next-Generation Insights and Approaches
ID
825311
Dates
05 mar 2017 - 09 mar 2017
Lieu
Breckenridge, Colorado, États-Unis
Résumé
Decades of both basic and applied research have unequivocally established the importance the kinase family of phosphotransferase enzymes in virtually every aspect of organismal homeostasis. From the initial characterization of ATP-dependent phosphorylation in the liver by Gene Kennedy in 1954, our understanding of the family has grown from the diverse perspectives of enzymology, biochemistry, biophysics, structural biology, genetics, cellular biology, pharmacology and physiology. Importantly, these advancements have yielded transformative therapeutic approaches to disease, most notably in the field of cancer where kinase inhibition is helping to fulfill the promise of precision medicine. Yet even today, our perspectives on the complexity of this class of enzymes continues to evolve, and many of the most exciting advancements in the field are being made by applying modern-day insights and technological approaches to the diverse roles the enzymes can play in health and human disease. This meeting will be devoted to exploring this innovative leading edge of kinase research, and will bring together leading researchers from academic, clinical and pharmaceutical settings to explore and define the new horizons in the field of kinase biology.
Contact
Tél.: [1 800-253-0685];     Email.: info@keystonesymposia.org
Sujets
Kinases, Drug Discovery, Kinase Signaling, Kinase Inhibitor
9.
 
The A to Z's of Microbial Control, Monitoring and Validation of Water Systems for Pharmaceuticals, Biologics, Medical Devices, Cosmetics, and Personal Care Products
ID
876856
Dates
08 mar 2017 - 09 mar 2017
Lieu
San Francisco, États-Unis
Résumé
All facilities manufacturing pharmaceuticals, biologics, medical devices, cosmetics, and personal care products are likely to have high purity water systems. In spite of this purity, microorganisms can flourish within these systems and lead to undesirable contamination of facility processes and their products. Of all the individuals at the facility, it is site’s microbiologists who should understand the microorganisms in water systems and how best to monitor and control them. Sadly, this is often not the case due to the lack of familiarity with biofilm and its impact on water system sampling, testing, sanitization, and routine maintenance. This lack of understanding of microbial control often leads to poor system designs, poor system sampling, poor system maintenance and poor sanitization practices, and as a result, ongoing microbial problems with the water.Note: Use coupon code < NB5SQH8N > and get 10% off on registration.
Contact
Referral;     Tél.: [8887172436];     Email.: referral@complianceonline.com
Sujets
Pharmaceutical water systems seminar, water system compliance seminar, water system microbial control, water system microbial monitoring, water system validation
10.
 
Ensuring Compliance with Advertising and Promotional Requirements for Drugs and Medical Devices
ID
876757
Dates
09 mar 2017 - 10 mar 2017
Lieu
San Francisco, États-Unis
Résumé
Federal regulation of the advertising and promotion of pharmaceuticals and medical devices reflects an aggressive attitude on the part of the regulators that demands, in turn, that industry be keenly aware of the legal and regulatory duties, as well as key recent trends in enforcement activities by the Federal Government. This course will explore in detail what FDA requires of drug and device firms as well as recent current hot buttons in FDA enforcement activity for the advertising arena.Note: Use coupon code < NB5SQH8N > and get 10% off on registration.
Contact
Referral;     Tél.: [8887172436];     Email.: referral@complianceonline.com
Sujets
FDA training seminar, FTC advertising seminar, advertising drugs, advertising medical devices, promotion drugs, promoting medical devices
11.
 
FDA's New Import Program for 2017 - Strict Precision
ID
876815
Dates
09 mar 2017 - 10 mar 2017
Lieu
Orlando, États-Unis
Résumé
The FDA continues to change its import program to better manage new problems and to use new procedures to make the whole process easier. The FDA and U.S. Customs and Border Protection (CBP) are relying more and more on computer programs to expedite the import process. When and how you use these programs can make a big difference in the net profit derived from even a single shipment. The new Voluntary Qualified Importer Program (VQIP) is one such example. Another example is CBP’s and FDA’s implementation of the Automated Commercial Environment (ACE) program became mandatory for importers in 2016. If you fail to correctly use new import procedures and programs, you will be operating under an expensive disadvantage.Note: Use coupon code < NB5SQH8N > and get 10% off on registration.
Contact
Referral;     Tél.: [8887172436];     Email.: referral@complianceonline.com
Sujets
FDA import regulations, FDA’s import legal requirements, U.S. Customs and Border Protection, CBP requirements, FDA warning letter, FDA import program
12.
 
Essentials Of USP Microbiology - Reading Between the Lines of the USP General and Information Microbiology Chapters
ID
876850
Dates
09 mar 2017 - 10 mar 2017
Lieu
San Francisco, États-Unis
Résumé
Learn essentials of USP microbiology - reading between the lines of the USP general and information microbiology chapters. Explore Form FDA 483s and Warning Letters for microbiological applications.Note: Use coupon code < NB5SQH8N > and get 10% off on registration.
Contact
Referral;     Tél.: [8887172436];     Email.: referral@complianceonline.com
Sujets
USP Microbiology, USP microbiology chapters, USP general, USP General Chapter Changes, USP Chapters, USP document
13.
 
Raw Material Requirements (Health Canada/USP/EP) in a cGMP Environment - Issues and Solutions
ID
876832
Dates
13 mar 2017 - 14 mar 2017
Lieu
San Francisco, États-Unis
Résumé
Raw material requirements in a cGMP environment are often overlooked as a company develops new products. Depending on the product being developed, e.g., tablets and capsules vs. biotechnology products, as few as fifteen to twenty or as many as sixty raw materials need to be sourced before the process can be moved from initiation through completion.Note: Use coupon code < NB5SQH8N > and get 10% off on registration.
Contact
Referral;     Tél.: [8887172436];     Email.: referral@complianceonline.com
Sujets
Raw material requirements in a cgmp environment training, compendial and non-compendial testing, ASQ on sample size, ICH Q9, health canada requirements
14.
 
Quality and GMP Compliance for Virtual Companies (Pharmaceutical, Medical Device & Biologics Industries)
ID
876766
Dates
16 mar 2017 - 17 mar 2017
Lieu
San Diego, États-Unis
Résumé
Today, many companies operate on an outsourcing model. This is very common for companies who are evolving from being mainly development-focused to a point where they are entering latter stages of Phase 2 or Phase 3 clinical trials, and plan to have a product ready for market approval in the coming months. Most such companies are small, and may not have deep expertise in QA and GMP compliance, relying on their partners to cover those areas. Companies who outsource the majority of operations through the use of Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs) and Contract Laboratories, however, remain responsible for the quality and compliance status of the products they send to the clinic or to the marketplace. Note: Use coupon code < NB5SQH8N > and get 10% off on registration.
Contact
Referral;     Tél.: [8887172436];     Email.: referral@complianceonline.com
Sujets
GMP compliance for virtual companies, contract manufacturing organizations (CMOs), contract research organizations (CROs), Contract Laboratories, quality agreement
15.
 
Keystone Symposia - Sex and Gender Factors Affecting Metabolic Homeostasis, Diabetes and Obesity
ID
825246
Dates
19 mar 2017 - 22 mar 2017
Lieu
Tahoe City, California, États-Unis
Résumé
There are fundamental aspects of metabolic homeostasis that are regulated differently in males and females, and influence both the development of diabetes and obesity and the response to pharmacological intervention. Still, most preclinical researchers avoid studying female rodents due to the added complexity of research plans. The consequence is the generation of data that risks being relevant to only half of the population. This is a timely moment to study sex differences in diseases as NIH leadership has asked scientists to consider sex as a biological variable in preclinical research, to ensure that women get the same benefit of medical research as men. The goal of this meeting is to fill a need in the scientific community by connecting interdisciplinary groups of scientists who normally would not have an opportunity to interact. This group includes investigators studying sex differences, the role of sex hormones, the systems biology of sex and the genetic contribution of sex chromosomes to metabolic homeostasis and diseases. Leaders of the pharmaceutical industry will present their views on sex-specific drug discovery. The meeting is expected to generate new knowledge and ideas on the importance of gender biology and medicine from a molecular standpoint to the population level, and to provide the methods to study them. It is intended to be a catalyst of a process that will lead to gender-specific treatments of metabolic diseases.
Contact
Tél.: [1 800-253-0685];     Email.: info@keystonesymposia.org
Sujets
sex, gender, metabolic homeostasis, diabetes, obesity, sex differences, estrogens, androgen, drug design, gender-specific medicine, metabolomics, genetics
Sujets apparentés
16.
 
8th Annual Biotherapeutics Analytical Summit
ID
829761
Dates
20 mar 2017 - 23 mar 2017
Lieu
Bethesda, États-Unis
Résumé
Today’s complex biologics formats and ever increasing regulatory demands necessitates that companies come up with the most efficient, accurate and robust analytical methods to characterize a molecule; find the most effective tools to assess the molecule’s physico-chemical properties to optimize its druggability and developability, and to ensure that the end product is consistently safe and efficacious when comparing between batches or between biosimilars and innovators. When it comes to batch-to-batch variation, as the saying goes, “process is the product” – process analytics and quality control are thus of biggest concern to manufacturers and regulators alike.
Contact
Bethany Gray;     Tél.: [781-972-5400];     Email.: chi@healthtech.com
17.
 
Root Cause Analysis and CAPA using 8-D Problem Solving Method
ID
876908
Dates
22 mar 2017 - 23 mar 2017
Lieu
Boston, États-Unis
Résumé
Errors and defects are a problem in virtually every industry. The goal of defect-free/error-free product or service delivery is the aim of every company. However, in order to eliminate defects or errors permanently, you must use a disciplined approach in order to ensure that the problem does not recur. One of the most widely-used tools is the 8 Disciplines (8D) methodology. 8D requires you to identify and fix the problem immediately (put a bandaid on it) while identifying the Root Cause(s), and take steps to address the problem in the short term as well as in the long term (permanent fix).Note: Use coupon code < NB5SQH8N > and get 10% off on registration.
Contact
Referral;     Tél.: [8887172436];     Email.: referral@complianceonline.com
Sujets
8-D Reporting, Reporting and Problem-Solving Technique, Root Cause Analysis, 8 Disciplines (8D) method, 8D framework, 8D technique, Root Cause Analysis (RCA)
18.
 
Managing Your FDA Inspection: Before, During and After
ID
876808
Dates
23 mar 2017 - 24 mar 2017
Lieu
Chicago, États-Unis
Résumé
FDA inspects many different kinds of firms. If the FDA regulates your product, they can show up at your lobby and say, “I am here to conduct an inspection.” What do you do? What have you done to prepare for an inspection? How do you deal with the investigator, including their personality? The scary part is having to explain the error of your ways to the FDA and above all, managing an administrative action, e.g., Warning Letter or Import Alert, or a legal action, e.g., civil money penalties, seizure, injunction or prosecution. This course will help you need to know and what you should do to survive an FDA inspection with the least possible pain.Note: Use coupon code NB5SQH8N and get 10% off on registration.
Contact
Referral;     Tél.: [8887172436];     Email.: referral@complianceonline.com
Sujets
FDA inspection seminar, FDA inspection, FDA 483, FDA warning letter, FDA investigator, FDA law, Regulatory Sanctions used by FDA, Prohibited Acts
19.
 
Creating FDA Compliant SOPs — FDA Compliant SOPs for Regulated Industry: How to Create High Quality SOPs that Your Team and FDA Auditors Will Love
ID
879320
Dates
23 mar 2017 - 24 mar 2017
Lieu
Boston, États-Unis
Résumé
SOP deficiencies are one of the top 5 findings in FDA audits. The entire Quality Management System (QMS) of an organization could be severely compromised due to SOP defects. Formal written Standard Operating Procedures (SOPs) are required both by the FDA and EMA. Almost every deficiency identified in FDA’s 483s and Warning Letters can be traced back to deficiencies in SOPs at an organization. SOPs are often inadequate, miss important elements, do not contain important tools to increase compliance with the SOPs and, many times, are hard for the personnel who follow them to understand. This workshop is applicable to all FDA-regulated organizations: clinical trials, manufacturing, advertisement, marketing, regulatory affairs, auditing, and laboratory testing.
Contact
Peter Brown;     Tél.: [+1 410 501 5777];     Email.: pbrown@fdamap.com
Sujets
FDA SOP, FDA Compliance, FDA Audit, FDA Inspection, FDA Regulations, FDA 483, FDA Warning Letters, Standard Operating Procedures
20.
 
Keystone Symposia - HIV Vaccines
ID
825214
Dates
26 mar 2017 - 30 mar 2017
Lieu
Steamboat Springs, Colorado, États-Unis
Résumé
Despite great progress in preventing and treating HIV, new infections continue to plague communities around the world, and the need for an HIV vaccine is as urgent as ever. Several large cohorts of HIV-infected individuals have enabled tremendous advances over the past five years in understanding immune responses to natural HIV infection. These advances have included the isolation of broad and potent anti-HIV antibodies, defining their developmental pathways, the generation of native-like Env trimers for immunization, and high-resolution structures of the envelope glycoprotein in complex with bnAbs. By 2017, many of these discoveries will have enabled new concepts to transition into human clinical trials, including passive monoclonal antibody therapy and novel immunization approaches. These platforms, incorporating improved technology for monitoring immune responses, will drive major advances in the vaccine field. This HIV Vaccines meeting will present the latest results from human clinical studies, along with the cutting-edge basic science behind such trials to highlight approaches that may lead to an HIV vaccine, and also reveal the molecular underpinnings of B and T cell-mediated immunity.
Contact
Tél.: [1 800-253-0685];     Email.: info@keystonesymposia.org
Sujets
HIV Vaccines, HIV, natural infection, transmission biology, immunogen platforms, b-cells, t-cells,
Sujets apparentés
21.
 
Effective Quality Oversight of Pharmaceutical Contract Manufacturing Organizations (CMOs)
ID
876899
Dates
30 mar 2017 - 31 mar 2017
Lieu
Tampa, États-Unis
Résumé
The globalization of the pharmaceutical supply chain has led increased us of Contract Manufacturing Organizations (CMOs). The use of CMOs provides many benefits; however, it can present unique compliance risks, particularly since the operations are not in your facility and therefore not under your direct control. The compliance risks are highlighted by FDA Warning Letter trends, the majority of which are related to serious compliance and data integrity issues at foreign CMO sites.Note: Use coupon code NB5SQH8N and get 10% off on registration.
Contact
Referral;     Tél.: [8887172436];     Email.: referral@complianceonline.com
Sujets
contract manufacturing pharmaceutical, CMO Oversight in Pharma Industry, CMO compliance, CMO business model, CMO Qualification Audit
22.
 
Understanding the Statistical Considerations for Quantitative ICH Guidelines
ID
876851
Dates
30 mar 2017 - 31 mar 2017
Lieu
Orlando, États-Unis
Résumé
This course is designed to introduce to individuals the understanding and interpretation of the statistical concepts with reference to certain quantitative ICH Guidelines that apply across laboratory (drug development) and clinical development (drug/device) procedures such as analytical methods in validation and acceptance criteria in calibration procedures, risk management and process monitoring as well as dealing with uncertainties and other relevant issues. It is not a course in statistics but introduces the participant to a hands on approach to the statistical techniques one uses, how they are applied and reasonably interpreted and understood. One will address the various challenges facing pharmaceutical and biotechnology companies when it comes to quantifying results in a meaningful interpretable manner through tabulations and graphical presentations. Note: Use coupon code NB5SQH8N and get 10% off on registration.
Contact
Referral;     Tél.: [8887172436];     Email.: referral@complianceonline.com
Sujets
Statistical considerations for quantitative ich guidelines training, quantitative measurement procedures, sensitivity of the sample size
23.
 
US GCP Fundamentals for Pharmaceutical and Biologic Companies
ID
876754
Dates
20 avr 2017 - 21 avr 2017
Lieu
San Francisco, États-Unis
Résumé
Good Clinical Practice (GCP) is a term used to describe a collection of various FDA regulations that govern the conduct of clinical trials. It includes regulations which apply to Sponsors and Contract Research Organizations (CROs) who run the trials, the clinical trial sites and Investigators who conduct the research, the Institutional Review Boards (
Contact
Referral;     Tél.: [8887172436];     Email.: referral@complianceonline.com
Sujets
FDA GCP inspections, good clinical practices seminar, GCP compliance, clinical trial sites, IRBs, good manufacturing practice, GMP, FDA inspection management
24.
 
FDA Scrutiny of Promotion and Advertising Practices
ID
876849
Dates
20 avr 2017 - 21 avr 2017
Lieu
Tampa, États-Unis
Résumé
If you go
Contact
Referral;     Tél.: [8887172436];     Email.: referral@complianceonline.com
Sujets
fda's advertising and promotion requirements, fda regulations for labelling, fda warning letter, fda legal authority, ftc, mass media, doj, off label, fda guidance
25.
 
Keystone Symposia - Modeling Viral Infections and Immunity
ID
825353
Dates
01 mai 2017 - 04 mai 2017
Lieu
Estes Park, Colorado, États-Unis
Résumé
Viral infection modeling has provided insights into the pathogenesis and treatment of HIV, HCV, HSV-2, CMV and other viruses. It has had impact in revealing the lifespan of infected cells, how rapidly virus is produced and cleared from the circulation, and the means for evaluating the effectiveness of antiviral treatments. HIV remains a global health threat and there is great interest in revealing features of the main HIV reservoir, latently infected cells and mechanisms of reducing the size of this reservoir by pharmacological means. Other important gaps in knowledge revolve around the cell-mediated and humoral immune responses to HIV, important for generating vaccines and broadly neutralizing antibodies as therapeutics, topics that will be discussed. Further, viral infections generally occur in tissues and thus the meeting will discuss imaging techniques and methods of modeling and analyzing spatial infection data, the role of tissue-resident memory cells, and important features of immune regulation, such as immune exhaustion, cytokine signaling between cells, and viral subversion of innate responses and escape from adaptive responses. The meeting will highlight what we believe are significant hurdles to curing viral infections and will bring together experimental virologists, physician scientists and modelers of various types and experience, groups that do not normally meet. It should foster new collaborations between experimentalists and theoreticians, and between theoreticians working on different viral infections or different aspects of viral infections, as well as help young scientists formulate new research directions and make connections with established senior scientists.
Contact
Tél.: [1 800-253-0685];     Email.: info@keystonesymposia.org
Sujets
modeling viral infections, immunity, viral infection, Modeling Immune Regulation, HIV, Modeling Cellular Immune Responses, Spatial Aspects of Infection
Sujets apparentés
26.
 
Navigating the Maze for Post-Market Compliance -- Complaint Handling, MDRs, Recalls and Proposed Guidance on FDA Risk Benefits
ID
878104
Dates
04 mai 2017 - 05 mai 2017
Lieu
Pittsburgh, États-Unis
Résumé
This interactive one and a half day course led by Ms. Rita Hoffman, Former FDA CDRH Recall Branch Chief, who has more than 36 years’ experience with the FDA will provide the participants tools to minimize risk of regulatory enforcement actions. During the seminar, Ms. Hoffman will explain proper handling of complaints reportable or non-reportable, product complaint handling and documentation, how and when to file Medical Device Reports (MDR), effective and appropriate communication with the appropriate regulatory agencies in the event of a recall. She will also discuss how to conduct a correction and removal actions to avoid a recall crisis, including required recordkeeping, expectation from FDA and other regulatory agencies in the event of a recall and key factors in implementing and maintaining compliance with the regulations and real life experiences of FDA. Note: Use coupon code NB5SQH8N and get 10% off on registration.
Contact
Referral;     Tél.: [8887172436];     Email.: referral@complianceonline.com
Sujets
medical device recalls seminar, medical device regulations seminar, medical device reporting, medical device complaint management, medical device complaint handling
27.
 
E&L USA 2017 — Extractables & Leachables USA 2017
ID
854261
Dates
09 mai 2017 - 11 mai 2017
Lieu
Falls Church, VA, États-Unis
Résumé
Extractables and leachables examination is continuously growing in importance. Given the current scruitny paid by governing bodies including the FDA and EMEA, understanding the best practice and guidelines to carry out extractables and leachables studies is imperative in order to eliminate risk and potential development delays.
Contact
Emma Nweton;     Tél.: [+44 (0) 1372 802016];     Email.: enewton@smithers.com
Sujets
extractables, leachables, analytical chemistry, pharmaceuticals, drug development, drug delivery, regulations, quality assurance, single-use systems, risk assessments, packaging, drug packaging
28.
 
PV (Pharmacovigilance) Audit Strategy Planning - A Practical Approach to Design and Implementation
ID
878147
Dates
11 mai 2017 - 12 mai 2017
Lieu
San Francisco, États-Unis
Résumé
The European Medicines Agency's (EMA) Guideline on good pharmacovigilance practices (GVP), Module IV requires that risk-based audits of the quality system be performed at regular intervals to assure that it complies with the established quality requirements and to determine its effectiveness. It includes audit of the pharmacovigilance system which is covered by the quality system. The GVP Modules are applicable to EU-based companies and any company marketing medicinal products on a global basis. The legally required risk based audit strategy shall cover all PV processes and tasks undertaken by or delegated to other departments, MAH affiliates, and third parties such as distributors, external service providers, partners (the PV Universe). The PV Audit Strategy Plan is used to prepare the PV audit program, i.e. annual PV Audit Schedule. Note: Use coupon code NB5SQH8N and get 10% off on registration.
Contact
Referral;     Tél.: [8887172436];     Email.: referral@complianceonline.com
Sujets
PV Audit Strategy Planning, The European Medicines Agency's (EMA) Guideline, Good Pharmacovigilance Practices (GVP), risk-based audits, GVP Modules, PV Universe
29.
 
Process Validation Guidance Requirements (FDA and EU Annex 15: Qualifications and Validation)
ID
878157
Dates
15 mai 2017 - 16 mai 2017
Lieu
Boston, États-Unis
Résumé
The Process Validation Guidelines (January 2011) and the EU Annex 15: Qualification and Validation (October 2015) outline the general principles and approaches the two regulatory bodies consider appropriate elements of process validation for the manufacture of human and animal drugs and biological products, including Active Pharmaceutical Ingredients (APIs). These guidances align Process Validation activities with a product lifecycle concept and with existing FDA and EU guidances, including the FDA/International Conference on Harmonization (ICH), Guidance for Industry, Q8 (R2) Pharmaceutical Development, Q9 Quality Risk Management, and Q10 Pharmaceutical Quality System. The lifecycle concept, new to these Guidances, link product and process development, qualification of the commercial manufacturing process, and maintenance of the process in a state of control during routine commercial production. These guidances also support process improvement and innovation through sound science and risk management. The new Process Validation Guideline/Practice incorporate elements of Process Validation as early as the Research and Development phase, and continues onward through Technology Transfer, into the Phase 1 IND Clinical Trial manufacturing phase, and ultimately into Phase 2 and 3, and then commercial manufacturing. Note: Use coupon code NB5SQH8N and get 10% off on registration.
Contact
Referral;     Tél.: [8887172436];     Email.: referral@complianceonline.com
Sujets
FDA Process Validation Guidance, EU Annex 15, Active Pharmaceutical Ingredients (APIs), International Conference on Harmonization (ICH)
30.
 
Manufacturing and Marketing OTC Drugs in Compliance with FDA Regulations (Updated to address recent Homeopathic Drug announcements by FDA & FTC)
ID
878156
Dates
16 mai 2017 - 17 mai 2017
Lieu
Philadelphia, États-Unis
Résumé
This interactive one-and-a-half-day seminar is intended to educate regulatory and quality professionals regarding the rather complicated regulations that distinguish Non-prescription Drugs from other products such as foods, cosmetics, dietary supplements and prescription drugs that sometimes contain the same ingredients. Recent FDA actions such as the banning of antibacterial soaps and ongoing programs that may impact manufacturers and private label distributors will be discussed. It will explain differences in the way homeopathic and conventional drugs are regulated and update participants on FDA’s application of GMP regulations to manufacturing low risk drugs that could be sold as cosmetics with the same ingredients, but different labeling. Note: Use coupon code NB5SQH8N and get 10% off on registration.
Contact
Referral;     Tél.: [8887172436];     Email.: referral@complianceonline.com
Sujets
Cosmeceuticals, dietary supplements, cosmetics, homeopathic OTCs, FDA regulations, FDA GMPS, good manufacturing practices, over the counter, low risk OTC drugs, warning letters, FDA enforcements actions, FDA marketing regulations
31.
 
Quality Control Laboratory Compliance - cGMPs and GLPs
ID
878141
Dates
18 mai 2017 - 19 mai 2017
Lieu
Philadelphia, États-Unis
Résumé
FDA inspection and oversight of quality control (QC) laboratories are essential elements of the agency’s evaluation of the compliance status of regulated companies representing multiple industries - pharmaceuticals, biologics, medical devices, as well as foods and cosmetics - as well as the contract QC laboratories which service these industries. Lack of compliance can result in severe regulatory actions, criminal liability, fines, and the inability to obtain product approvals. Note: Use coupon code NB5SQH8N and get 10% off on registration.
Contact
Referral;     Tél.: [8887172436];     Email.: referral@complianceonline.com
Sujets
Quality Control Lab regulations, QC Lab regulations, FDA QC Lab requirements, FDA lab regulations, Good Laboratory Practices, GLP, cGMP, Current Good Manufacturing Practices
32.
 
Pre-Filled Syringes West Coast
ID
877316
Dates
05 jui 2017 - 06 jui 2017
Lieu
San Diego, États-Unis
Résumé
SMi Group are thrilled to announce the return of Pre-Filled Syringes West Coast 2017 which arrives to California on June 5th & 6th.

Following on from sell-out shows in Europe and Boston, Pre-Filled Syringes West Coast will once again gather a global audience of medical device experts and PFS industry leaders to discuss new developments and showcase cutting edge advances, keeping you at the forefront of a booming industry. The competitive PFS market has sparked great improvements as devices strive for higher quality, safety, and patient satisfaction. Innovation and excellence is requested at every level making Pre-Filled Syringes West Coast the perfect platform to strengthen knowledge in key principles such as human factor engineering, manufacturing and complex biologics, whilst honing in on emerging trends for parenteral devices, including auto injectors, pens, pumps and smart devices. We will also be welcoming expertise from the likes of Nemera, Nipro PharmaPackaging, Terumo, Worrell, Zeon, Allergan, MedImmune, Xeris Pharmaceuticals, Amgen, Eli Lilly, Genentech, Ferring, Roche and more.

Contact
Teri Arri;     Tél.: [+44 (0)20 7827 6000];     Email.: tarri@smi-online.co.uk
Sujets
prefilled syringe, pre-filled syringe, autoinjector, human factors, device development, innovation, strategy, extractables, leachables, patient safety, compliance, biosimilar, parenteral, packaging, combination products, lyophilisation, freeze drying, injectable, injectable devices, syringe, extractables and leachables, E&L, PFS, drug device, drug delivery, combination products, sterilization, needle, component, glass syringe, cop syringe, container, formulation, device development, human factors, manufacturing, device technology, medical device, parenteral drug, plastic, qbd, drug delivery, infusion, vial, cop, sterilization, clogging
33.
 
Practical Approaches to Quality by Design (QbD) for Pharmaceutical Process Research, Development and Manufacturing
ID
858806
Dates
13 jui 2017 - 15 jui 2017
Lieu
Chicago, États-Unis
34.
 
FASEB SRC — From Unfolded Proteins in the Endoplasmic Reticulum (ER) to Disease
ID
871000
Dates
18 jui 2017 - 23 jui 2017
Lieu
Saxtons River, VT, États-Unis
Résumé
This SRC focuses on the endoplasmic reticulum (ER) and its functions. The purpose of the meeting is to merge recent developments in molecular biology, cell biology, genetics, and physiology aimed at unraveling the complexities of secretory protein folding, ER stress pathways, lipid signaling, and ER membrane biology, and how failure of these processes lead to pathologies and disease. This SRC will include talks from outstanding scientists, both invited and selected from poster abstracts. The meeting is known for its active discussions, not only during the presentation session, but also during the free afternoons, and especially during the poster sessions. Posters will remain on display during most of the conference and a selection will be advertised in oral poster pitches. The venue, Vermont Academy, is excellently suited for the mingling of junior and established scientists, which will be strengthened by meet-the-speaker sessions that allow discussions of both career issues and science.
Contact
FASEB SRC Staff;     Tél.: [3016347010];     Email.: src@faseb.org
Sujets
biochemistry, Pharmacology
Sujets apparentés
35.
 
9th International Conference and Exhibition on Pharmacovigilance & Drug Safety
ID
869764
Dates
17 jul 2017 - 19 jul 2017
Lieu
Munich, États-Unis
Contact
programe cordinator;     Tél.: [702-508-5200];     Email.: pharmacovigilance@pharmaceuticalconferences.org
Sujets
Advanced Regulatory Compliance in Pharmacovigilance operations and innovations Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business
36.
 
International Vaccines Congress
ID
857191
Dates
27 jul 2017 - 28 jul 2017
Lieu
Chicago, États-Unis
Résumé
PULSUS is the publisher of peer reviewed scientific, technical, and medical journals and magazines. Since establishment 1984, has been instrumental in healthcare and medical dissemination. PULSUS expanded with the support from scientific societies and open its arm to conduct global medical and healthcare meetings. With immense please and support, PULSUS is honored to announced it International Vaccines Congress, which will be going to held in Chicago, USA during July 27-28, 2017.
Contact
Annah Brwon;     Email.: vaccinescongress@protonmail.com
Sujets
vaccines Congress, Vaccines Conference 2017, Vaccines Conference USA
Sujets apparentés
37.
 
Pharmacology Studies 2017 — International Conference on Pharmacology & Toxicology Studies
ID
859584
Dates
07 aou 2017 - 09 aou 2017
Lieu
Philadelphia, États-Unis
Résumé
Scientific Synergy Conferences are delighted to welcome you all to the
Contact
Scientific Synergy;     Tél.: [+1-888-623-5051];     Email.: pharmacology@scientificsynergy.com
Sujets
Pharmacology Studies 2017, Pharmacology Conference, Toxicology Conference, Scientific Synergy USA, Pharmacology Conference Philadelphia, Pharmacology Congress USA, Clinical Pharmacology event, Drug Toxicology, Pharmacology Case Reports, Forensic Toxicology.
38.
 
Formulation & Drug Delivery USA Congress
ID
871437
Dates
14 sep 2017 - 15 sep 2017
Lieu
Boston, États-Unis
Résumé
Oxford Global are proud to present our Formulation & Drug Delivery USA Congress, taking place on 14 – 15 September 2017 in Boston. Over 150 delegates representing leading pharmaceutical organisations, biotech companies and internationally renowned research & academic institutions will be present to discuss and network. Over 40 case studies and presentations focused on exploring regulatory guidelines of both large and small molecule formulations, future applications of protein and peptide formulations, recent advancements in nanoparticles as drug delivery systems, combination drug delivery devices and improving the bioavailability of compounds.
Contact
Guillaume Alonso;     Tél.: [+44 (0) 1865 248 455];     Email.: g.alonso@oxfordglobal.co.uk
Sujets
drug formulation, drug delivery, small molecules, large molecules
39.
 
ICCP — 5th International Conference on Clinical Pharmacy
ID
858171
Dates
23 oct 2017 - 24 oct 2017
Lieu
Florida, États-Unis
Résumé
Clinical Pharmacy Conference aims to bring together leading academic scientists, researchers, and research scholars to exchange and share their experiences and research results about all aspects of Clinical Pharmacy. It also provides the disciplinary forum for researchers, practitioners and educators to present and discuss the most recent innovations, trends, and concerns, practical challenges encountered and the solutions adopted in the field of Clinical Pharmacy. All honorable authors are kindly encouraged to contribute to and help shape the conference through submissions of their research abstracts, papers, and e-posters. Also, high-quality research contributions describing original and unpublished results of conceptual, constructive, empirical, experimental, or theoretical work in all areas of Clinical Pharmacy are cordially invited for presentation at the conference. The conference solicits contributions of abstracts, papers, and e-posters that address themes and topics of the conference, including figures, tables, and references of novel research material. The conference abstracts and proceedings book and certificate of presentation will be distributed to the conference participants at the conference registration desk. In the light of this theme, the conference series aims to provide a forum for international researchers from various areas of biomedical, pharmaceutical, and clinical sciences by providing a platform for critical analysis of new data, and to share latest cutting-edge research findings and results about all aspects of Clinical Pharmacy.
Contact
Victor Badoni;     Tél.: [7025085200 Ext: 8047];     Email.: badonivictor@outlook.com
Sujets
Pharma Conferences, Pharmacy Conferences, Clinical Pharmacy Conferneces, Pharmaceutical Conferences
40.
 
Practical Approaches to Quality by Design (QbD) for Pharmaceutical Process Research, Development and Manufacturing
ID
858884
Dates
31 oct 2017 - 02 nov 2017
Lieu
Boston , États-Unis
41.
 
International Pharmaceutical Conference and Expo
ID
875932
Dates
14 nov 2017 - 16 nov 2017
Lieu
Philadelphia,, États-Unis
Résumé
iPharma 2017 cordially welcomes you to the City of Philadelphia, USA during November 14-16, 2017. Conference will witness academicians and business professionals discussing the soundest issues related to pharmaceuticals and will offer unparalleled business opportunities and access to new markets in Health Science.
Contact
serena martin;     Tél.: [6193784793];     Email.: serena@ipharmaconference.com
Sujets
Pharmaceutical, Drug Discovery, Drug Delivery Systems, Pharmaceutical Nanotechnology, Drug Therapy, Pharmaceutical Formulations, Clinical Trials, Neuropharmacology, Biopharmaceutical, Nutraceuticals, Pharma Medicines
42.
 
Biomarkers congress 2017 — Annual World Congress on Biomarkers & Clinical Research
ID
867784
Dates
27 nov 2017 - 28 nov 2017
Lieu
Atlanta, États-Unis
Résumé
PULSUS brings in a new spin on conferences by presenting the latest scientific improvements in Biomarkers and its clinical researches. Listen to motivating keynotes from thought leaders, pioneers across the globe. Atlanta is all set for an amazing event as PULSUS proudly presents the “Annual World Congress on Biomarkers & Clinical Research” on November 27-28, 2017. PULSUS cordially welcome researchers, academicians, students and business professionals in the field of BIOMARKERS from around the world to participate in the upcoming BIOMARKERS CONGRESS 2017. The meeting for this year will revolve around the theme “Explore the latest Biomarkers development in health and clinical research” thus relaying the most cutting edge findings in the field of Biomarkers Research.
Contact
Rachel Mathews;     Email.: america@cmesociety.com
Sujets
Biomarkers Conference, Biomarkers Conference 2017, Biomarkers Conference December, Cancer Biomarkers, Cancer Conferences, Cancer Conferences 2017, Biomarkers Events, Biomarkers Society Conferences, Biomarkers Congress
Sujets apparentés

États-Unis: liste de tous les évènements/conférences.

RNA Therapeutics conference
Superbugs & Superdrugs Conference
Pharmaceutical Freeze Drying Technology, 8th & 9th May 2017, Copthorne Tara Hotel, London UK
Pain Therapeutics, 22nd & 23rd May 2017, Copthorne Tara Hotel, London UK
Pre-Filled Syringes West Coast, 5th & 6th June 2017, Hyatt Regency Mission Bay, San Diego, California, USA

Bon à savoir...

Vous pouvez insérer un encadré afin de diffuser vos évènements et services dans cet espace.

Dernière mise à jour: 21 Février 2017